About this trial
Autism is a neurodevelopmental disorder (NDD) characterized by two key features: persistent deficits in communication and social interaction, and restricted, repetitive patterns of behavior, interests, and activities. Ninety-five percent of children aged 3 to 6 with autism spectrum disorder (ASD) have sensory peculiarities. In adulthood, this figure remains at 90%. This atypical sensory processing has been part of the DSM diagnostic criteria since 2013.
Each sense can be affected by hypo- or hypersensitivity. In the continuum of this particular sensory processing, pain, which is defined as an unpleasant sensory and emotional experience, can be very present but also difficult to detect and manage. It is now established that there are other characteristics that impact pain in ASD: information processing time may be longer, referred to as "latency time," but there are also difficulties in representing the body schema and difficulties in identifying and/or interpreting perceptions. Expression may be atypical, and there may be an apparent lack of reaction to pain due to a lack of flexibility.
All of these characteristics themselves vary over time (with age, the menstrual cycle, lack of sleep, fatigue, etc.), to the point that even pain specialists in pain clinics may not recognize them.
It is therefore essential to carry out appropriate, individualized assessments.
The scientific literature refers to the high frequency of painful events in ASD. For example, the prevalence of gastrointestinal disorders with their associated abdominal pain is significantly higher. Recent research has revealed that 82.4% of children and adolescents with ASD have at least one gastrointestinal symptom. Researchers have found that children with ASD are almost eight times more likely to have one or more chronic gastrointestinal symptoms than typically developing children. There are also more common comorbidities that facilitate or maintain chronic pain: Ehler Danlos syndrome and hypermobility spectrum disorders, IBD, ADHD, post-traumatic stress disorder, depression, migraines and tension headaches, anxiety disorders, epilepsy, small fiber pathologies, nutritional deficiencies, musculoskeletal disorders, etc.
Mutations in certain genes involved in ASD (such as SCN9A, SHANK3, and CNTNAP2) lead to impaired neuronal function, producing different responses to pain, as demonstrated in both mouse and human models. The links between ASD and chronic pain are therefore complex. Sometimes it is the unusual characteristics of the pain that could lead to a diagnosis of ASD.
The concept of central sensitization (CS), which underlies the type of pain known as "nociplastic," helps explain the state of pain hypersensitivity and pathologies such as fibromyalgia and irritable bowel syndrome. In 2022, Grant et al. found that 21% of adults with ASD surveyed in the cohort reported having a diagnosis of central sensitization syndrome (CSS), but 60% scored at or above the cut-off. This suggests that CS symptoms such as pain and fatigue are very common in people with autism, and perhaps more prevalent than in the general population. For example, three-quarters of women diagnosed with ASD and/or ADHD in childhood report chronic pain in adulthood.
The issue is the disability associated with this chronic pain and the impairment of quality of life.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Medical diagnosis of ASD without established intellectual developmental disorder
Patient affiliated with a social security system or beneficiary of such a system
Understanding of written French (good comprehension of self-questionnaire questions)
Disqualifiers
Intellectual developmental disorder that prevents understanding of self-administered questionnaires
Individuals subject to legal or judicial protection measures or unable to express their consent
Trial population
patient aged 18 or older who has been diagnosed with an autism spectrum disorder without an intellectual disability,
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Determine the prevalence of signs of central sensitization in adults on the autism spectrum without intellectual developmental disorders.
Percentage of patients with a CSI score ≥ 40 Total Score CSI :\[0-100\] A CSI score \> 40 points defines clinically significant central sensitization. The score is divided into intervals: 0 to 29 = subclinical CS, 30 to 39 = mild CS, 40 to 49 = moderate CS, 50 to 59 = severe CS, 60 to 100 = extreme CS.
Secondary outcomes
Determine the average level of central sensitivity in adults on the autism spectrum, with at least one diagnosis of SSC
Average CSI score (part A) in this subgroup Total Score CSI (part A): \[0-100\] The score is divided into intervals: 0-29 = subclinical central sensitisation, 30-39 = mild central sensitisation, 40-49 = moderate central sensitisation, 50-59 = severe central sensitisation, 60-100 = extreme central sensitisation.
Determine the average level of central sensitivity in adults on the autism spectrum without a diagnosis of SSC
Average CSI score (part A) in this subgroup Total Score CSI (part A) :\[0-100\] The score is divided into intervals: 0-29 = subclinical central sensitisation, 30-39 = mild central sensitisation, 40-49 = moderate central sensitisation, 50-59 = severe central sensitisation, 60-100 = extreme central sensitisation.
Determine the prevalence of SSC diagnoses
Percentage of patients with at least one SC diagnosis (part B of the CSI) Total Score SCI (part B) : \[0-10\].This section provides additional clinical information, but does not count toward the numerical score.
Determine the average anxiety level
Average HAD-A Anxiety Score Total Score HAD-A : \[0-21\] Score \[0 - 7\]: no anxiety and/or depressive disorders. Score \[8- 10\]: questionable symptoms. Score \[11 - 21: confirmed anxiety and/or depressive disorders of varying severity.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.